IP Library Granted Patent US 8,993,615
Granted Patent B2
US 8,993,615 · App. 13/058,171 · Granted Mar 31, 2015

Compositions and methods for treatment of neurodegenerative disease

Inventors: Donald J. Zack (Baltimore, MD); Zhiyong Yang (Baltimore, MD); Cynthia Berlinicke (Baltimore, MD); Harry Quigley (Baltimore, MD)
Assignee: The Johns Hopkins University
A61K45/06A61K31/00A61K31/404
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,993,615
App. No.
13/058,171
Granted
Mar 31, 2015
Kind
B2
Abstract

Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed.

Claims (17)

1. A method for treating a neurodegenerative disease or disorder, the method comprising administering to a subject in need of treatment thereof an effective amount of a compound represented by the following structure (I):

wherein:

R 1 is hydrogen;

R 2 is selected from the group consisting of hydrogen, halo, and —S(O) 2 NR 13 R 14 ;

R 3 is hydrogen;

R 4 is hydrogen;

R 5 is alkyl;

R 6 is selected from the group consisting of hydrogen and —C(O)R 10 , or R 5 and R 6 combine to form an alkyl group consisting of —(CH 2 ) 4 —;

R 7 is alkyl;

R 10 is selected from the group consisting of —N(R 11 )(CH 2 ) n R 12 and —NR 13 R 14 ;

R 11 is H;

n is independently 1, 2, 3 or 4;

R 12 is —NR 13 R 14 ; and

R 13 and R 14 are independently alkyl or aryl, or R 13 and R 14 may combine to form a heterocyclo group;

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the compound of formula (I) is selected from the group consisting of:

3. The method of claim 1 , wherein the treating of the neurodegenerative disease or disorder promotes survival of retinal ganglion cells (RGCs), promotes neurite outgrowth of RGCs, protects RGCs against NMDA excitotoxicity, protects RGCs from axon injury induced cell death, reduces RGC loss secondary to optic nerve injury, blocks or attenuates activation of apoptotic pathways, and combinations thereof.

Assignments (1)
CONFIRMATORY LICENSE Recorded Dec 11, 2017
From: JOHNS HOPKINS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044824/0903 →
Continuity (3)
Provisional Application 61188362 · Aug 8, 2008
Provisional Application 61142377 · Jan 4, 2009
Related Publication 20110172206A1 · Jul 14, 2011